2-(4-isothiocyanato-phenyl)-6-methyl-imidazo[1,2-a]pyridine | 64730-40-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-isothiocyanato-phenyl)-6-methyl-imidazo[1,2-a]pyridine
• 英文别名: 2-(4-Isothiocyanatophenyl)-6-methylimidazo[1,2-a]pyridine
• CAS: 64730-40-1
• 化学式: C₁₅H₁₁N₃S
• 分子量: 265.338
• InChiKey: XMVHLDFTAFJTDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Substituted imidazo[1,2-A] pyridine derivatives
  申请人：——

  公开号：US20020188128A1

  公开（公告）日：2002-12-12

  The present invention is a series of novel compounds of formula I and a method of treatment or prevention of a mGluR5 receptor mediated disease by administering an therapeutically effective amount of a compound formula 1 wherein R 1 and R 2 are selected from hydrogen, (C 1-6 )-alkyl, halogen, hydroxy, (C 1-6 )-alkoxy and A is defined the description, or a pharmaceutically acceptable salt thereof.

  本发明涉及一系列新颖的化合物，化学式为I，并通过给予有效治疗剂量的化合物化学式1来治疗或预防mGluR5受体介导的疾病的方法，其中R1和R2从氢、(C1-6)-烷基、卤素、羟基、(C1-6)-烷氧基中选择，A在描述中有定义，或其药用盐。
• Substituted imidazo [1,2-a] pyridine derivatives
  申请人：——

  公开号：US20030212096A1

  公开（公告）日：2003-11-13

  The present invention is a series of novel compounds of formula I and a method of treatment or prevention of a mGluR5 receptor mediated disease by administering an therapeutically effective amount of a compound formula 1 wherein R 1 and R 2 are selected from hydrogen, (C 1-6 )-alkyl, halogen, hydroxy, (C 1-6 )-alkoxy and A is defined the description, or a pharmaceutically acceptable salt thereof.

  本发明涉及一系列新型化合物I的方法，以及通过给予化合物公式1的治疗有效量或预防mGluR5受体介导的疾病的方法，其中R1和R2选择自氢，(C1-6)-烷基，卤素，羟基，(C1-6)-烷氧基和A在说明中定义，或其药学上可接受的盐。
• Novel compounds
  申请人：——

  公开号：US20030149047A1

  公开（公告）日：2003-08-07

  The invention provides compounds of general formula (I) wherein Q, R, R 1 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了一般式（I）的化合物，其中Q，R，R1，R4，R5，R6，R7和R8如规范中所定义，其制备过程，包含它们的制药组合物以及它们在治疗中的使用。
• Substituted imidazo[1,2-a]pyridine derivatives
  申请人：——

  公开号：US20040180921A1

  公开（公告）日：2004-09-16

  The present invention is a series of novel compounds of formula I and a method of treatment or prevention of a mGluR5 receptor mediated disease by administering an therapeutically effective amount of a compound formula 1 wherein R 1 and R 2 are selected from hydrogen, (C 1-6 )-alkyl, halogen, hydroxy, (C 1-6 )-alkoxy and A is defined the description, or a pharmaceutically acceptable salt thereof.

  本发明涉及一系列公式I的新化合物以及通过给予公式1中化合物的治疗有效量来治疗或预防mGluR5受体介导的疾病的方法，其中R1和R2选择自氢、(C1-6)烷基、卤素、羟基、(C1-6)烷氧基，A的定义如说明书所述，或其药学上可接受的盐。
• IMIDAZO [1,2-A]-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1381363B1

  公开（公告）日：2004-12-08